Established in 2005, Avivia is a specialized pharmaceutical development company engaged in CRO service activities, drug repositioning, repurposing and reformulation. Over the past fifteen years, the company has built a solid reputation recognized for its R&D flexibility and ‘out-of-the-box’ approach towards complex and challenging analytical and pharmaceutical development projects. Today, we are the preferred partner for many big pharma, specialty pharma, generic drug companies, academic centra, and smaller drug development firms. Our offices and state-of-the-art laboratories are located in Nijmegen, The Netherlands, in close proximity to the German and Belgian borders.

Avivia leadership team

The Avivia management team combines the experiences of executives and a top-tier advisory board with extensive backgrounds in managing, developing and exiting successful businesses in the pharmaceutical and generics industry.

Lee Ayres – Managing Director

Lee Ayres is responsible for overall management of the company, strategy, marketing and business development. Before joining Avivia, Lee was CTO and co-founder of Encapson, a company specializing in coating for medical devices, where he led development of the Sono-Coat technology. Alongside being a member of the Management Team, as CTO he led the business development, sales, marketing and technical development activities. The Sono-Coat technology was acquired by LipoCoat in 2024. Lee holds a Master’s Degree in Chemistry from University of York and a PhD from the Radboud University of Nijmegen in Bio-Organic Chemistry.

Johannes (‘Hans’) J. Platteeuw – Supervisory Board, Business Development

Mr. Platteeuw holds a master’s degree in Chemistry from the University of Nijmegen, The Netherlands. He started his career at Synthon BV as Project Manager of pharmaceutical product development and later became the company’s Head of Galenical R&D. In 2004 he moved to Dafra Pharma, a private company specialized in antimalarial medication where he acted as Director R&D and was instrumental for the launch of Co-Arinate. In 2005, he started Avivia BV, a company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products.

Manager Avivia Excipia

Menno Wiltink – Sientific Director

Mr. Wiltink is a Partner in Avivia who has 25 years of experience in the pharmaceutical R&D with expertise in analytical research and support, API, Excipient and drug product characterization and troubleshooting, predictive dissolution testing, preclinical evaluation and equivalence selection. He was heading the Analytical R&D Department at Synthon BV and studied Analytical Sciences at the University in Amsterdam and Environmental Analysis at the Van Hall Larenstein, University of Applied Sciences. He joined Avivia as a partner in 2014 and set up analytical R&D CRO lab services, as well as a platform for a dissolution support and  method development, and Excipia for excipient characterization and reverse engineering of medicines.

Dennie van den Heuvel, Avivia CRO

Dennie van den Heuvel – Development Director

Mr. van den Heuvel is a Partner in Avivia who has over 20 years working experience in the pharmaceutical industry and is an expert in formulation development. Related topics range from preclinical development up to the market formulation including production, IP and regulatory requirements. He held different positions at Intervet/Akzo-Nobel and Synthon and has extensive experience in project management, working in and leading/coaching interdisciplinary teams (CMC, Toxicology, Clinical, Regulatory, Analytics). He is an inventor of 25+ patents in name of Synthon. He joined Avivia as a partner in 2014 and set up pharmaceutical R&D CRO lab services and Siloxia for silica based technologies.

Avivia CRO

Hans van der Steen – Operations

Mr. van der Steen holds a bachelor’s degree in analytical chemistry from the Fontys higher education of Eindhoven. After obtaining more than 15 years of experience in analytical chemistry in the pharmaceutical and excipient industry, Organon NV, CP Kelco and Synthon, he joined Avivia in 2015. His area of interest and expertise includes API and excipient characterisation, analytical research & support and drug product troubleshooting & development. He joined Avivia as a partner in 2014 and is now responsible for operations management.


Avivia is growing so we are constantly looking for Junior and Senior Scientists (Pharmaceutical Development) to join our team and to help us achieve our goals.  We are keen on people who say what they’ll do and do it, are 100% focused on results and success, have a strong personality (but not too strong), and want to work in pharma for the right reasons.  If you are interested to join our team, don’t hesitate to let us know. Get in touch.

Current Job Openings


At Avivia we are proud of our development facilities and equipment, which enable us to perform formulation and analytical R&D at the highest level. New developments enable us to also offer the production of small-scale GMP drug product batches. We welcome all interested parties to visit us for a tour through our state-of-the-art facilities!

Besides knowledge centers Excipia and Siloxia Avivia has three complementary pharmaceutical specialty R&D lab service divisions:

Avivia CRO Offices
Avivia CRO Pharmaceutical Analysis HPLC
Avivia CRO Pharmaceutical Laboratory Services
Avivia CRO Apparatus 3 USP III